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Homocysteine and hematological indices in
hemodialysis patients at Al-Shifa hospital, Gaza Strip
Abstract
Background: Renal failure constitutes one of the ten leading causes of
death in the Gaza strip with mortality rate of 2.8%. Although
hyperhomocysteinemia has been strongly linked to end stage renal disease,
biochemical test is restricted to monitoring kidney function. Therefore,
introducing homocysteine as a biomarker of ESRD in Gaza hospitals is
recommended.
Objective: To assess homocysteine and hematological indices in
hemodialysis patients at Al-Shifa hospital, Gaza Strip.
Material and methods: This case-control study comprised 60
hemodialysis patients and 60 healthy controls. Questionnaire interview was
applied. Serum homocysteine, urea and creatinine, white blood cell (WBC)
count, red blood cell (RBC) count, hemoglobin, hematocrit, mean corpuscular
volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular
hemoglobin concentration (MCHC), platelet count, prothrompin time (PT),
activated partial thromboplastin time (APTT) and international normalized ratio
(INR) were determined. Data were analyzed using SPSS version 18.0.
Results: End stage renal disease was more prevalent among lower
educated and unemployed individuals, families with low income as well as
among individuals with family history of the disease. Clinical data showed that
hypertension and diabetes are the most common self-reported disorders
among the hemodialysis patients. Serum homocysteine was significantly
higher in cases compared to controls (50.8±9.7 vs. 13.1±3.7 μmol/l, P=0.000).
Serum urea and creatinine were also found to be significantly higher in cases
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(169.6±42.4 and 9.96±2.40 mg/dl, respectively) compared to controls
(27.4±7.1 and 0.77±0.14 mg/dl) with P=0.000. White blood cell count, MCHC
and platelet count were significantly increased in cases compared to controls
(7.18±1.37 x103 cell/l, 33.8±1.2 mg/dl and 266.3±104.2 x109 L vs 5.95±1.37
x103 cell/l, 28.4±2.0 mg/dl and 222.0±54.1 x109 L) with P=0.017, P=0.000
and 0.045, respectively. In contrast, RBC count, hemoglobin, hematocrit and
MCH showed significant decreases in cases(3.12±0.54 x106 cell/l, 8.9±1.5
gm/dl, 26.3±4.6% and 28.6±2.9 pg) compared to controls (4.03±0.37 x106
cell/l, 12.8±1.6 gm/dl, 45.0±4.6% and 31.9±4.4 pg) with P<0.01. Prothrompin
time and INR were significantly higher in cases compared to controls
(16.2±2.6 sec and 1.23±0.17 vs 13.5±0.4 sec and 0.97±0.07, P=0.000),
whereas APTT was decreased in cases (25.3±5.3 vs 32.6±2.1 sec, P=0.000).
Homocysteine levels were higher among lower educated and unemployed
individuals, families with low income as well as among individuals with family
history of ESRD (P<0.01). Homocysteine was positively correlated with urea
(r=0.827, P=0.000), creatinine (r=0.842, P=0.000), WBC count (r=0.338,
P=0.008), MCHC (r=0.789, P=0.000) and platelet count (r=0.369, P=0.000)
whereas negative correlations were found between homocysteine and RBC
count (r=-0.648, P=0.000), hemoglobin (r=-0.733, P=0.000), hematocrit (r=-
0.836, P=0.000) and MCH values (r=-0.402, P=0.001). In addition,
homocysteine showed positive correlations with PT (r=0.564, P=0.000) and
INR (r=0.657, P=0.000) and negative correlation with APTT (r=-0.690,
P=0.000).
Conclusions: Serum homocysteine was significantly higher in
hemodialysis patients compared to controls. Homocysteine was positively
correlated with urea, creatinine, WBC count, MCHC, platelet count, PT and
INR, and negatively correlated with RBC count, hemoglobin, hematocrit, MCH
and APTT.
Keywords: Homocysteine, hematological indices, hemodialysis, Gaza Strip.
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حالة الحمض األمیني الھوموسستین والمؤشرات الدمویة عند مرضى الدیال 
قطاع غزة–في مستشفى الشفاء الدموي 
ملخص الدراسة
%، 2.8: یعد الفشل الكلوي أحد األمراض العشرة األولى المؤدیة إلى الوفاة في قطاع غزة بمعدل مقدمة
وعلى الرغم بأن ارتفاع مستوى الحامض األمیني الھوموسستین مرتبط بقوة بمرضى الدیال الموي، إلى أن أن 
تصرة لرصد وظائف الكلى فقط، لذلك یوصى بإدخال فجص الھوموسستین كعالمة  الفحوصات البیوكیمیائیة مق
بیولوجیة للمرحلة األخیرة لمرضى الكلى في مستشفیات غزة.
تھدف الدراسة إلى قیاس حالة الحمض األمیني الھوموسستین والمؤشرات الدمویة عند مرضى الدیال :الھدف
قطاع غزة.–الدموي في مستشفى الشفاء 
شخص من مرضى 60)، المجموعة المرضیة تحتوي على دراسة مشھدةمنھج الدراسة (ق واألدوات:الطر
شخصا من األصحاء كعینات ضابطة، وقد تم الحصول على النتائج من خالل المقابلة 60الدیال الدموي، 
ریاتینین، عدد الشخصیة لمرضى الدیال الدموي واألصحاء، وقد تم قیاس مستویات الھوموسستین، الیوریا والك
، الحجم الكروي الوسطيخالیا الدم البیضاء، عدد خالیا الدم الحمراء، الھیموجلوبین، الھیماتوكریت، 
، عدد الصفائح، زمن البروثرومبین، الزمن ھیموغلوبین الكریة الوسطي، تركیز ھیموغلوبین الكریة الوسطي
الجزئي للثرومبو بالستین المنشط و نسبة التطبیع الدولیة.
.SPSS-18.0تم تحلیل البیانات والنتائج التي تم الحصول علیھا باستخدام البرنامج اإلحصائي 
أظھرت النتائج بأن المرحلة األخیرة من مرض الكلیة تعد أكثر انتشارا بین األشخاص العاطلین عن النتائج: 
العمل واألقل تعلما، العائالت ذات الدخل المحدود باإلضافة إلى األشخاص ذوي تاریخ عائلي للمرض. كما 
ضى الدیال الدموي، كما أن أظھرت البیانات السریریة بأن الضغط والسكر ھما المرضان األكثر شیوعا بین مر
تركیز كل من الھوموسستین والیوریا والكریاتینین أعلى في الحاالت المرضیة بالمقارنة مع األصحاء وھذه 
ھیموغلوبین الكریة الوسطيالنتائج ذات داللة إحصائیة، ولوحظ من النتائج بأن عدد خالیا الدم البیضاء، تركیز 
في الحاالت المرضیة بالمقارنة مع األصحاء، وھذه النتائج ذات داللة ، قد ارتفعت وعدد الصفائح الدمویة
إحصائیة أیضا. وفي المقابل بینت النتائج بأن معدالت عدد خالیا الدم الحمراء، الھیموجلوبین، الھیماتوكریت و
تائج إلى ترتفع عند مرضى الدیال الدموي بالمقارنة مع األصحاء. كما أشارت النھیموغلوبین الكریة الوسطي
عدل التطبیع العالمي أعلى في الحاالت المرضیة بالمقانة مع األصحاء وھذه مثرومبین وروأن كل من زمن الب
النتائج ذات داللة إحصائیة، وعلى النقیض كان زمن الثرومبوبالستین الجزئي المنشط أقل في الحاالت المرضیة 
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مستوى الھوموسستین كان أعلى بین كل من األشخاص منھ في األصحاء وھذه النتائج ذات داللة إحصائیة. 
العاطلین عن العمل، األقل تعلما، العائلت ذات الدخل المحدود بالإلضافة إلى األشخاص ذوي تاریخ عائلي 
للمرض، وھي نتائج ذات داللة إحصائیة. وأوضحت النتائج وجود عالقة إیجابیة بین الحامض األمیني 
، الكریاتینین، عدد خالیا الدم البیضاء، تركیز متوسط الھیموجلوبین الكرويالھوموسستین وكل من الیوریا
في حین وجدت عالقة عكسیة بین مستویات الحامض األمیني الھوموسستین، مع كل وعدد الصفائح الدمویة.
ج وجود من عدد خالیا الدم الحمراء، الھیموجلوبین، الھیماتوكریت ومتوسط الھیموجلوبین الكروي. وبین النتائ
عالقة إیجابیة بین الھوموسستین وكل من زمن الروثرومبین ومعدل التطبیع العالمي، وعالقة سلبیة مع زمن 
الثرومبوبالستین الجزئي المنشط.
وجد ارتفاع ذو داللة إحصائیة في مستوى الحامض األمیني الھوموسستین عند مرضى الدیال االستنتاجات:
كما وجدت عالقة إیجابیة بین مستویات الھوموسستین وكل من الیوریا، الدموي بالمقارنة مع األصحاء، 
زمن الصفائح الدمویة،الكریاتینین، عدد خالیا الدم البیضاء، تركیز متوسط الھیموجلوبین الكروي،
البروثرومبین ومعدل التطبیع العالمي. وأشارت النتائج لوجود عالقة عكسیة بین الھوموسستین وكل من عدد 
الدم الحمراء، الھیموجلوبین، الھیماتوكریت، متوسط الھیموجلوبین الكروي وزمن الثرومبوبالستین خالیا 
الجزئي المنشط.
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The kidneys are responsible for filtering and excreting wastes from the blood.
Without proper functioning, toxic waste products will accumulate and the
patient will die. Therefore, the kidneys are vital to maintain life. Kidney
diseases were classified into acute kidney disease (AKD) and chronic kidney
disease (CKD). Acute kidney disease is a syndrome characterized by rapid
decline (hours to days) in glomerular filtration rate (GFR), retention of
nitrogenous waste products, and perturbation of extracellular fluid volume and
electrolyte and acid-base homeostasis (Dennis et al., 2005). Chronic kidney
disease is a progressive loss in renal function over a period of months or
years, and it may lead to one of its recognized complications such as
cardiovascular disease, anemia or pericarditis (Nurko, 2006 and Herzog et
al., 2011). Chronic kidney disease (CKD) is a well-known risk factor for end-
stage renal disease, ESRD (Iseki et al., 2003).
National Kidney Foundation (NKF, 2002) classified the severity of CKD into
five stages according to the level of GFR, with stage 1 being the mildest and
usually causing few symptoms (GFR≥ 90 ml/min/1.73 m2) and stage 5 being a
severe illness with poor life expectancy if untreated (GRF <15 ml/min/1.73 m2
or dialysis). Stage 5 CKD is also called established CKD and is synonymous
with the now outdated terms ESRD or chronic kidney failure (CKF). In renal
failure, filtrate formation decreases or stops completely. Because toxic wastes
accumulate quickly in the blood when the kidney tubule cells are not working,
hemodialysis by an artificial kidney is necessary to cleanse the blood while
the kidneys are shut down (Marieb, 2003).
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Hemodialysis is the most common treatment option for ESRD patients. This
treatment involves blood being taken from the body and circulated through a
machine with an artificial kidney called a dialyzer, which performs ultrafiltration
and diffusion through a semipermeable membrane (The Kidney Foundation
of Canada, 2004). Under such circumstances, kidney dialysis is typically
administered using a fixed schedule of three times per week (Abo Shamala,
2008). Among the common complications seen in persons with ESRD, are
anemia mainly due to loss of erythropoietin production (Nurko, 2006;
Jonathan, 2010; Lovcić et al., 2011 and Portolés et al., 2013),
abnormalities in WBC, platelets functions (Kaw and Malhotra, 2006 and
Turkmen et al., 2010), and uremia (Depner, 2005 and Locatelli and
Canaud, 2012).
The number of patients being treated for ESRD globally was estimated to be
2,786,000 at the end of 2011 and, with a 6-7% growth rate, continues to
increase at a significantly higher rate than the world population. Of these
2,786,000 ESRD patients, approximately 2,164,000 were undergoing dialysis
treatment (hemodialysis or peritoneal dialysis) and around 622,000 people
were living with kidney transplants. In the USA, Japan and the European
Union, dialysis patient population growth rates between 2010 and 2011 were
in a range of 1– 4% and, as such, were significantly lower than growth rates in
regions such as Asia, Latin America, the Middle East and Africa (Fresenius
Medical Care, 2011). The Palestinian Health Annual Report (2010) showed
that renal failure constitutes one of the ten leading causes of death in the
Gaza strip with mortality rate of 2.8% (Ministry of Health, MOH, 2010).
Homocysteine is a sulphur containing intermediary amino acid which is
derived by the demethylation of methionine (Shipchandler et al. 1995). The
primary source of methionine is animal protein (Hankey and Eikelboom,
1999). The normal range of homocysteine is 5 to15 μmol/L (Ueland et al.,
1993 and Graham et al., 1997). Elevated serum homocysteine beyond the
normal range (>15 μmol/L) is traditionally referred to as
3
hyperhomocysteinemia.  Recently, hyperhomocysteinemia has been linked to
different stages of CKD including ESRD (Van Guldener, 2006; Vieira et al.,
2010 and Paterson, 2011).
Although CKD is prevalent in the Gaza strip (MOH, 2010), few recent studies
targeted the disease. Abo Shamala, (2008) studied parathormone, calcium
and phosphorus levels in hemodialysis patients at Al-Shifa hospital, Gaza-
Palestine. Abu Nada, (2012) investigated homocysteine levels in chronic
kidney disease patients in Gaza Governorate. Muhaisen et al. (2012)
assessed risk factors of cardiovascular disease among children with chronic
kidney disease in Gaza Strip. The present study will be the first to asses
homocysteine level and hematological indices in hemodialysis patients from
Gaza Governorate, Gaza Strip.
1.2 General objective
To asses homocysteine and hematological indices in hemodialysis patients at
Al-shifa hospital, Gaza Strip.
1.3 Specific objectives
1. To determine homocysteine level in hemodialysis patients compared to
healthy controls.
2. To determine urea and creatinine concentrations in hemodialysis patients
and controls.
3. To measure complete blood count (CBC) in hemodialysis patients and
controls.
4. To asses prothrombin time (PT), activated partial thromboplastin time
(APTT) and international normalized ratio (INR) in hemodialysis patients in
comparison to controls.




1. In the last decade the number of hemodialysis patients in the Gaza Strip
has been doubled with mortality rate of 2.8% (MOH, 2010 and Personal
Communication, 2013).
2. In Gaza Strip only one study have been carried out on hemodialysis
patients without speculation of the status of homocysteine and hematological
parameters in the disease (Abo Shamala, 2008). Therefore, this will be the
first study to investigate homocysteine and hematological indices in
hemodialysis patients in Gaza Governorate.
3. Assessments of homocysteine and hematological indices in hemodialysis






2.1.1 Location and structure
The kidneys are small, dark red organs lie against the dorsal body wall
beneath the parietal peritoneum in superior lumbar region where they receive
some protection from the lower part of the rib cage (Figure 2.1). An adult
kidney (about 12 cm long, 6 cm wide, and 3 cm thick) has a medial
indentation (the hilus) in which there is two renal arteries, renal vein, and
ureter (Marieb, 2003). The kidney has three regions, outer granulated layer
called renal cortex, renal medulla that consists of cone shaped tissue masses
called medullary pyramids, and renal pelvis which is a central space or cavity
that is continuous with the ureter (Mader, 2004).
Figure 2.1. Location and structure of the kidney (Marieb, 2003)
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Each kidney contains approximately one million tiny structures called
nephrons (Figure 2.2). Nephrons are responsible for the processes of
filtration, reabsorption, and secretion that go on in the kidney to form the urine
product (Marieb, 2003). The nephron consists of two main structures, a
glomerulus, which is a knot of capillaries, and a renal tubule. The closed end
of the renal tubule is enlarged and cup-shaped and completely surrounds the
glomerulus. This portion of the renal tubule is called Bowman's capsule. In
order from Bowman's capsule they are the proximal convoluted tubule, loop of
Henle, and the distal convoluted tubule. Most of the nephron is located in the
cortex, only portion of the loops of Henle dip into the medulla. Urine from
many nephrons is collected in the collecting ducts, which deliver the final urine
product into the calyces and pelvis of the kidney (Thibodeau and Patton,
1999; Mader, 2004 and Guyton and Hall, 2011).
Figure 2.2. Structure of the nephron (Guyton and Hall, 2011)
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2.1.2 Functions of the Kidney
The kidneys excrete natural waste products, including urea and creatinine, as
well as foreign substances like alcohol and drugs, from the body. The kidneys
also regulate the water and electrolyte (dissolved salts) balance and the acid-
base balance (Faratro et al., 2004). The kidneys also produce and secrete
important hormones, including renin, erythropoietin, and vitamin D. Renin is
involved in regulating blood pressure, erythropoietin is used to stimulate the
bone marrow to produce red blood cells, and vitamin D is needed to absorb
the calcium from food in the intestine (Faratro et al., 2004 and Barrett et al.,
2010).
2.2 Kidney disease
Renal disease may be acute or chronic. Acute renal failure occurs when the
kidney fails suddenly, but this may be a temporary problem, and after a short
period of treatment the patient may recover. Chronic renal failure results from
an abnormal loss of renal function over months to years. Chronic renal
disease is rarely reversible and leads to progressive decline in renal function
(Faratro et al., 2004). Reduction in renal mass leads to hypertrophy of the
remaining nephrons with hyperfiltration, and the GFR in these nephrons are
transiently at supranormal levels, that may worsen renal function (Lawrence
et al., 2003).
2.2.1 Chronic kidney disease
Levey et al. (2005) defined CKD as kidney damage or GFR<60 ml/min/1.73
m2 for 3 months or more, irrespective of cause. Kidney damage in many
kidney diseases can be ascertained by the presence of albuminuria, defined
as albumin-to-creatinine ratio >30 mg/g in two of three spot urine specimens.
Chronic kidney disease has been classified into various stages for the
purpose of prevention, early identification of renal damage and institution of
preventive measures for progression of the primary damage and appropriate
guidelines for instituting management for prevention of complications in
severe CKD (Vijayakumar et al., 2007). National kidney foundation classified
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CKD into 5 stages according to the level of GFR (Table 2.1). For stages 1 and
2, kidney damage was assessed by spot albumin-to-creatinine ratio (National
Kidney Foundation, NKF, 2002).






1 Kidney damage with
normal or increased
≥ 90
2 Kidney damage with mild
reduction of GFR
60-89
3 Moderate reduction of GFR 30-59
4 Severe reduction of GFR 15-29
5 Kidney failure (ESRD) <15 or dialysis
GFR: Glomerular filtration rate. Adopted from National Kidney Foundation
(NKF, 2002).
2.3 End stage renal disease
End stage renal disease, a continuum of CKD, is defined as irreversible
kidney failure treated with dialysis or transplantation (Anderson et al., 2009).
Smeltzer and Bare (2004) defined ESRD as the final stage of chronic renal
failure were in there is a progressive, irreversible deterioration in renal
function in which the body’s ability to maintain metabolic and fluid and
electrolyte balance fails, resulting in uremia. The National Kidney Foundation
(2002) rated ESRD as the last and the fifth stage among CKD, which is based
on the presence of kidney damage and level of kidney function whereas GFR
<15 ml/min/1.75m². When the kidneys cease functioning, as in end stage
renal disease, medications, diet, and fluid restriction will help to optimize the
patient's health and wellbeing, but dialysis or kidney transplantation also need
to occur (Krueger, 2007 and Ganesh and Lee, 2011).
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2.3.1 Prevalence of end stage renal disease
End stage renal disease prevalence is highest in Taiwan with around 2,850
patients per million population (p.m.p.), closely followed by Japan with around
2,490 p.m.p. and then the USA with around 1,970 p.m.p. It averages about
1,040 p.m.p. in the 27 countries that make up the European Union (EU). In
Asia, Latin America, the Middle East and Africa, dialysis patient population
growth rates between 2010 and 2011 were higher than growth rates in
regions such as the USA, Japan and the European Union (Fresenius
Medical Care, 2011). The Palestinian Health Annual Report (2010) showed
that renal failure constitutes one of the ten leading causes of death in the
Gaza strip with mortality rate of 2.8% (MOH, 2010). The number of the
hemodialysis patients in Gaza strip, in year 2003 was 204 patients. In the year
2008, this figure was increased to reach about 361 patients, of them about
180 patients were in the hemodialysis unit at Al-Shifa hospital, which had 32
hemodialysis machines (Abo Shamala, 2008). Nowadays, there are 420
patients maintained on regular hemodialysis in Gaza strip, of them about 230
patients were in the hemodialysis unit at Al-Shifa hospital, which had 33
hemodialysis machines (Personal Communication with Renal Unit at Al-
Shifa Hospital, 2013).
2.3.2 Causes of end stage renal disease.
End stage renal disease has many causes that vary from one patient to
another. The most common causes include (Sandra, 2005; Hyman, 2006;




• Obstruction of the urinary tract by stones or cancer.
• Diabetes mellitus.
• Obesity.
• Polycystic kidney disease.
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• Medications such as the use of some analgesics regularly over long
durations of time.
2.3.3 Treatment of end stage renal disease
The most important treatment alternatives for ESRD include hemodialysis,
peritoneal dialysis and kidney transplantation. The populations of ESRD
patients, dialysis patients and patients living with a transplanted kidney have
increased steadily over the past years, whereby consistently more than three-
quarters of all ESRD patients were treated by dialysis (Fresenius Medical
Care, 2011).
2.3.3.1 Hemodialysis
Hemodialysis is a method that is used to achieve the extracorporeal removal
of waste products such as creatinine and urea and free water from the blood
by an artificial kidney machine when the kidneys are in a state of renal failure.
The basic principle of the artificial kidney is to pass blood through minute
blood channels bounded by a thin membrane. On the other side of the
membrane is a dialyzing fluid into which unwanted substances in the blood
pass by diffusion (Guyton and Hall, 2011). Hemodialysis is found in two
variants: conventional hemodialysis, where patients receive hemodialysis in a
clinic three times a week for 4 hours/session, and nocturnal hemodialysis,
where patients are trained to do their own hemodialysis while they sleep, 5–6
nights/week (Crawford and Lerma, 2008). Hemodialysis is a relatively safe
procedure, but there are several complications that can occur including
hypotension, cardiac arrhythmias, muscle cramps, anaphylaxis, and restless
leg syndrome (Crawford and Lerma, 2008). However, with proper monitoring
and prompt treatment, many of these complications can be avoided. Of note,
better glycemic control (HbA1c < 7.5 %) has been shown to predict better




Compared to hemodialysis, peritoneal dialysis offers lower risk of death
across all subgroups for the first 1–2 years of dialysis and is now
recommended for use as the initial modality of dialysis in the majority of
ESRD patients due to the lower prevalence of infections and better
preservation of residual renal function (Chung et al., 2009). The two common
choices for peritoneal dialysis are continuous ambulatory peritoneal dialysis
and automated continuous cycling peritoneal dialysis, both of which function
by infusing peritoneal dialysis fluid in the peritoneal cavity and draining it 4–6
hours later with the number of exchanges varying according to patient size,
peritoneal membrane permeability, and residual kidney function (Crawford
and Lerma, 2008).
2.3.3.3 Kidney transplantation
Is the surgical procedure of placing a fully functioning kidney into a person
with ESRD. This procedure is usually an elective one, performed in patients
who have undergone careful preoperative assessment and preparation. The
transplanted kidney may originate from a deceased donor or from a related or
unrelated person (Cueto-Manzano AM, 2007). Several recent studies have
demonstrated significantly improved patient and allograft survival as well as
lower rates of delayed graft function or acute rejection episodes in those with
preemptive transplants versus those who were on dialysis for a period of time
before transplantation (Gill et al., 2004 and Baura, 2012).
2.4 Hematological complications of ESRD
End stage renal disease is associated with a variety of hemopoietic changes.
Anemia is common among ESRD patients, with more than 95% of individuals
on dialysis receiving some form of anemia treatment (Zadeh and Aronoff,
2009 and Anees et al., 2010). The main contributing factor to anemia in renal
failure is loss of erythropoietin production (Nurko, 2006). Hemolysis may
result from a number of biochemical and toxic insult during the dialysis
12
procedure. The life span of red blood cells is reduced by approximately one
third in hemodialysis patients (Marticorena et al., 2004). Other factors include
suppression of bone marrow erythropoiesis, hematuria, and gastrointestinal
blood loss (Suresh et al., 2012). Abnormalities in white blood cell and platelet
functions lead to increased susceptibility to infection and easy bruising.
Patients with ESRD develop increased bleeding tendency, which is
characterized by defective interaction of platelets with damaged sub
endothelium due to impaired platelet functions (Mohsin et al., 2010). In this
context, conventional hemostasis parameters PT, APTT and INR were
disturbed and thrombotic complications and bleeding abnormalities are
common among patients undergoing hemodialysis (Holley, 1999; Rios et al.,
2010 and Alghythan and Alsaeed, 2012).
2.5 Homocysteine
2.5.1 Definition and structure
Homocysteine is an amino acid with the formula HSCH2CH2CH(NH2)CO2H.
It is a homologue of the amino acid cysteine, differing by an additional
methylene (-CH2-) group. Homocysteine exists at neutral pH values as a
zwitterion: Betatine form of (S)-Homocysteine and (R)-Homocysteine (Figure
2.3).
Figure 2.3. Structure of homocysteine. Betatine form of (S)-
Homocysteine (left) and (R)-Homocysteine (right) (Champe et al., 2008).
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2.5.2 Biosynthesis of homocysteine
Homocysteine is not obtained from the diet (Selhub, 1999). Instead, it is
biosynthesized from methionine via a multi-step process (Figure 2.4). First,
methionine receives an adenosine group from ATP, a reaction catalyzed by
Sadenosyl- methionine synthetase, to give S-adenosyl methionine (SAM).
SAM then transfers the methyl group to an acceptor molecule, (i.e.,
norepinephrine as an acceptor during epinephrine synthesis, DNA
methyltransferase as an intermediate acceptor in the process of DNA
methylation). The adenosine is then hydrolyzed to yield L-homocysteine. L-
homocysteine has two primary fates: conversion via tetrahydrofolate (THF)
back into L-methionine or conversion to L-cysteine (Champe et al., 2008).




Several homocysteine species have been identified in human plasma
including albumin-(protein)-bound, free circulating disulfides and sulfhydryl
forms (Maron & Loscalzo, 2007). However, total homocysteine plasma
concentrations are commonly reported in the literature as current analytical
methodology involves the reduction of homocysteine disulfide bonds,
quantifying all forms as free total homocysteine (Perla-Kajan, et al., 2007
and Maron and Loscalzo, 2009).
2.5.4 Metabolism of homocysteine
The metabolism of homocysteine can be divided into three distinct pathways
(Figure 2.5): the remethylation of homocysteine to methionine by the vitamin
B12 dependent methionine synthase; the transsulfuration pathway, converting
homocysteine to cystathionine and then cysteine via vitamin B6 dependent
cystathionine β-synthase enzyme; in the liver and kidneys, homocysteine can
be remethylated back to methionine by betaine-homocysteine
methyltransferase (Maron & Loscalzo, 2009).
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Figure 2.5. Homocysteine metabolic cycle. Sited from Maron & Loscalzo,
(2009).
2.5.5 Homocysteine values
The American Heart Association released an advisory statement classifying
total homocysteine plasma concentrations as follows: 5-15 μmol/L
homocysteine as normal, 16-30 μmol/L homocysteine as moderate, 31-100
μmol/L homocysteine as intermediately elevated and total homocysteine
levels above 100 μmol/L as severely elevated concentrations (Malinow et al.,
1999).
2.5.6 Hyperhomocycteinemia
Hyperhomocysteinemia, is defined as total homocyteine concentrations
elevated above 15μmol/L. Plasma homocysteine concentration exhibits a
strong relationship with (indices of) renal function. Hyperhomocysteinemia has
been implicated in patients with CKD (van Guldener, 2006 and Vieira et al.,
2010). There are several indications that whole body homocysteine
metabolism is altered in renal insufficiency (van Guldener, 2005). Stable
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isotope studies in dialysis patients have shown a decreased homocysteine
clearance by transsulfuration and decreased homocysteine remethylation and
methionine transmethylation (van Guldener et al., 1999 and Stam et al.,
2005). Several, but not all, prospective studies have linked
hyperhomocysteinemia to adverse cardiovascular outcomes in renal failure
patients. Hyperhomocysteinemia has been also associated with the
pathogenesis of cardiovascular disease (Al-obaidi et al., 2001; Lubos et al.,
2007 and coldea et al., 2011). Deficiencies of the vitamins folic acid (B9),
pyridoxine (B6), or B12 (cyanocobalamin) can lead to hyperhomocysteinemia
(Brosnan, 2004 and Abraham et al., 2010). Hyperhomocysteinemia also
occur in the rare hereditary disease homocystinuria and in the
methylenetetrahydrofolate reductase polymorphism genetic traits (Qi et al.,
2003). The latter is quite common (about 10% of the world population) and it
is linked to an increased incidence of thrombosis and cardiovascular disease,
which occurs more often in people with above minimal levels of homocysteine
(about 6μmol/L).
2.6 Related studies
Bostom et al., (1995) determined fasting total plasma homocysteine in 24
ESRD patients on dialysis, and 24 age, gender, and race matched controls
with normal renal function. Mean plasma homocysteine was markedly higher
in the ESRD patients versus controls (22.7 vs. 9.5 pmol/l). End stage renal
disease patients were 33 times more likely than controls to have
hyperhomocysteinemia (>15.8 pmol/l) (95% confidence interval, 5.7-189.6).
Hematological evaluation of hemodialysis patients showed that sustained
increases in hematocrit (Hct) levels are associated with improved patient
survival (Ma et al., 1999).
Chou et al. (2000) found that the mean concentrations of plasma total
homocysteine in Taiwanese hemodialysis patients (21.3±4.3 µM) were
statistically higher than in age-matched normal subjects (11.0±2.9 µM).
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Nasri and Baradaran (2006) demonstrated a significant inverse correlation of
serum homocysteine with white blood cell count (r=-0.34, P=0.036) and a
significant positive correlation of serum homocysteine with body mass index
(r=0.35, P=0.039) in 25 hemodialysis patients. In addition, Nasri (2006)
showed a significant positive correlation of platelet count with serum
homocysteine in 39 hemodialysis patients (r=0.35, P=0.044).
Cabarkapa et al. (2007) examined 105 subjects: 73 patients in different stage
of chronic renal failure, 31 of them on hemodialysis, and 32 subjects as a
control group. The results showed high prevalence of hyperhomocysteinemia
in chronic renal failure patients, especially with reduction of glomerular
filtration rate over 50% of the surface normalized value. Khanam et al. (2007)
found that the mean hemoglobin concentration, hematocrit and total count of
red blood cells were significantly lower in three stages of chronic renal failure
(CRF) patients (n=65) with anemia compared to those of healthy subjects
(n=25). All the hematological parameters showed positive correlation with
creatinine clearance in all three stages of CRF.
Ali et al. (2008) demonstrated an increase of hemoglobin, hematocrit, red cell
count, PT and APTT in Sudanese patients after dialysis session. In addition,
Shojaei et al. (2009) found that homocysteine level in Iranian patients on
maintenance hemodialysis was 33% higher on average than the reference
value.
The relationship of hemoglobin and homocysteine levels and mortality of
patients on hemodialysis was assessed (Anees et al., 2010). Fifty patients on
hemodialysis and 20 healthy individuals were enrolled in the study. Forty-
three patients (86%) were anemic (hemoglobin < 11 g/dL). Serum ferritin was
high (> 500 ng/mL) in 33 patients (66%). Mortality was 28% in one year (33%
in anemic patients versus no death among patients with a hemoglobin level
greater than 11 g/dL). The relative risk of mortality was increased by 1.58 with
every one g/dL decrease in hemoglobin level. All of the patients had a high
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homocysteine level, and a significant difference was observed between the
homocysteine levels of the patients on hemodialysis and the control group
(P<0.001). In addition, De Almeida et al. (2011) found that the total
prevalence of hyperhomocysteinemia in 70 renal failure patients on dialysis
treatment was 85.7%. Homocystien was positively correlated with albumin
and creatinine.
Suresh et al. (2012) assesed the hematological changes in 50 patients
suffering from chronic renal failure compared to 50 age and sex matched
controls. In chronic renal failure patients, RBC count, hemoglobin
concentration, hematocrit and platelet count where significantly (P<0.05)
reduced, whereas total leukocyte count was reduced but not statistically
significant. The concentration of serum creatinine shows negative correlation
with all the haematological parameters. And the degree of changes depends
on the severity of renal failure. In addition, Alghythan and Alsaeed, (2012)
observed that most of hematological parameters elevated after hemodialysis.
More significantly, PT, APTT and fibrinogen were found to increase post
hemodialysis while there was a concurrent decrease of platelet counts. In
addition, Baseline data on co-morbidities and anemia management in 4591
European hemodialysis patients on hemodialysis >180 days were collected
(Locatelli et al., 2012). Mean hemoglobin (Hb) concentration was 11.0 g/dl;
53% patients had hemoglobin concentration ≥11 g/dl. Higher hemoglobin
concentrations were associated with decreased relative risk for mortality and
hospitalization. Patients with hemoglobin <10 g/dl were 29% more likely to be





The present study is a case-control design.
3.2 Study population
The study population comprised hemodialysis patients diagnosed as end
stage renal disease on hemodialysis and healthy controls.
3.3 Setting of the study
The hemodialysis unit at Al-Shifa hospital in the Gaza strip.
3.4 Sample size
A total of 60 patients (34 males and 26 females) maintained on hemodialysis
were included in the present study. Sixty healthy individuals (34 males and 26







The participants were given a full explanation about the purpose of the study
and assurance about the confidentiality of the information obtained through
the questionnaire and blood analysis.
3.7 Data collection
3.7.1 Body mass index
The body weight of each individual dressed in light clothing without shoes was
weighed using a carefully calibrated electrical balance (Seca model 762,
Germany). The height of each was measured using vertical measuring rod.
Body mass index was calculated as the ratio of body weight in Kg/height in
meter square. Individuals with BMI=18.5-24.9 were considered to have normal
weight, individuals with BMI=25.0-29.9 were classified overweight, individuals
with BMI≥30.0 were considered obese (World Health Organization, WHO,
2000).
3.7.2 Questionnaire interview
A meeting interview was used for filling in a questionnaire which designated
for matching the study need (Annex 1). All interviews were conducted face to
face by the researcher himself. During the survey the interviewer explained
any of the questions that were not clear. Most questions were one of two
types: the yes/no question, which offers a dichotomous choice; and the
multiple choice questions, which offer several fixed alternatives (Backestrom
and Hursh-Cesar, 1981). The validity of the questionnaire was tested by six
specialists in the fields of nephrology, public health and hematology. The
questionnaire included personal information (age, gender, marital status and
education), socioeconomic characters (employment, family income/month,
family history of ESRD and smoking) and clinical data (hemodialysis duration,
hemodialysis frequency and other chronic disease). A pilot study was done
prior to beginning real data collection to know the length and clarity of the
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questionnaire and to evaluate the outcome. Ten cases were interviewed. At
the end of the pilot study, a comprehensive revision to questionnaire was
made and modified as necessary. The pilot subjects were not included in the
study.
3.7.3 Blood sampling and processing
Blood samples were collected by the researcher himself from all the subjects
who agreed to participate in the study (before hemodialysis sessions for the
patients). Nine ml blood were obtained from each subject and divided into
EDTA tube (2 ml) for CBC analysis, Sodium citrate 3.2% tube for PT and
APTT determination in plasma (3 ml) and vacutainer plain tube (4 ml) that was
left for a while to allow blood to clot. Then, serum samples were obtained by
centrifugation at 3000 rpm for 15 minutes. Serum homocysteine, creatinine
and urea were determined.
3.8 Hematological analyses
3.8.1 Complete blood count
Blood samples were processed by an automatic counter for hemoglobin
concentration and other whole blood component concentrations (cell dyn
1800, USA).
3.8.2 Determination of prothrombin time (PT)
Principle
Single-stage prothrombin time measures the clotting time of test plasma after
the addition of the thromboplastin reagent containing calcium chloride. The
reagent supplies a source of "tissue thromboplastin," which activates factor
VII, and is therefore sensitive to all stage II and III factors. Deficiencies in
stage I factors (VIII, IX, XI, and XII) are not detected by the test.
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International sensitivity index (ISI)
The International Committee for Standardization in Hematology and the
International Committee on Thrombosis and Hemostasis have agreed on
recommendations for the reporting of prothrombin time results based upon an
International Sensitivity Index (ISI) for thromboplastin reagents and an
International Normalized Ratio (INR). Thromboplastin reagents are assigned
an ISI value by calibrating them against an international reference
preparation, (IRP, 67/40) which by definition has an ISI = 1.0. The ISI value
assigned to commercial thromboplastin reagents, therefore, defines a
comparative slope, or relative sensitivity, in comparison to the reference
thromboplastin. The lower the ISI value, the more "sensitive" is the reagent.
By knowing the ISI of a particular thromboplastin reagent, the ratio can be
calculated which would have been found if the IRP 67/40 had been used as
the reagent.
This is termed the international normalized ratio (INR), and is determined by:
INR = RISI = Ratio ISI = Patients PT (s)Normal PT (s)




3.2% buffered sodium citrate was used.
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Procedures
1. Fifty μl plasma into cuvette was pipetted.
2. Plasma was pre-warmed for 3 minutes.
3. Cuvette was transferred to measuring position.
4. 100 μl pre-warmed hemostat thromboplastin-si was added (measurement
starts automatically).
5. The result is displayed in seconds and INR.
Normal value
The expected range is between 11 and 14 s.
3.8.3 Determination of activated partial thromboplastin time
(APTT)
Principle
The APTT test measures the clotting time of test plasma after the addition of
APTT reagent, then allowing an "activation time," followed by the addition of
calcium chloride. Deficiencies of approximately 40% and lower of factors VIII,
IX, XI and XII will result in prolonged APTT. Heparin, in the presence of







3.2% buffered sodium citrate was used.
Procedures
1. Fifty μl plasma was pipetted into cuvette.
2. Plasma was pre-warmed for 1-2 minutes
3. Fifty μl APTT reagent was added to plasma.
4. Incubate for 3-5 minutes (for consistent results, test all plasmas with the
same time)
5. Cuvette was transferred to measuring position.
6. Fifty μl pre-warmed calcium chloride was added (the measurement starts
automatically).
7. The result was displayed in seconds and ratio.
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3.9 Biochemical analyses
3.9.1 Determination of serum homocysteine
Serum homocysteine was determined by enzymatic colorimetric method for
the quantitative determination of homocysteine (Refsum, 2002), using Globe
diagnostics kit, Italy.
Principle
The Globe Diagnostics Enzymatic Test for the quantitative homocysteine
determination is based on a series of enzymatic reactions causing a decrease
in absorbance value due to NADH oxidation to NAD+. HCY concentration in
the sample is directly proportional to the quantity of NADH converted to NAD+
(ΔA 340nm). The enzymatic reactions are the following:
s-Methyltransferase
T(HCY) (HCY)free
SAM Hydrolase + Adenosine deaminase
(HCY)free + SAM* Methionine + SAH**
Glutamatedehydrogenase
SAH + NADH Inosine +NAD+
* SAM = S-Adenosyl-methionine






















*Nicotinamide Adenine Dinucleotide (NADH)
**Homocysteine (HCY)
Analytical procedure
About  0.5  ml  of  serum  was  transferred  to  the  Mindray  BS-300






Serum      (μI) 9
Incubation period (s) 25 cycles (5 minutes)





The ΔA (A2 - A1) calculated for blank and each calibrator against its
concentration (concentrations are reported on the calibrator vial label).
Results was found by comparing the sample ΔA against the plotted curve. A
curve fitting system software was suggested to achieve more precise results.
Reference value
National Institute of Standards and Technology (NIST) standardized study
shows 15 μmol/l as the cut-off value for normal level of homocysteine for
adults.
3.9.2 Determination of serum urea
Principle
Serum urea was determined by using "Urease-GLDH": enzymatic UV test,
according to Thomas method (Thomas, 1998) using DiaSys reagent kits.
Urea + 2H2O → 2NH4 + 2HCO
2-Oxoglutarate + NH4 + NADH → L-Glutamate + NAD+ + H2O
Standarization NIST
























Measurement: against distilled water.
 Ten µl of standard (sample or control) was added to 1 ml of working
reagent and mixed well.
 The mixture was incubated for 30 sec then absorbance (A1) was
recorded.
 After exactly further 60 sec the absorbance (A2) was measured.
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Calculation
∆A = (A1 – A2) sample or standard
Urea (mg/dl) =
Reference value
(Palestinian Clinical Laboratory Test Guide, PCLTG, 2005)
Child 5 - 30 mg/dl
Adult 13 - 43 mg/dl
3.9.3 Determination of serum creatinine
Serum creatinine was determined by using kinetic test without
deproteinization according to Newman and Price method (Newman and
Price, 1999) using DiaSys reagent kits.
Principle
Creatinine forms a colored orange-red complex in an alkaline picrate solution.
The difference in absorbance at fixed times during conversion is proportional
to the concentration of creatinine in the sample.
Creatinine + Picric acid → creatinine picrate complex




Concentrations are those in the final test mixture.
ConcentrationReagent
0.16 mol/lR1: Sodium hydroxide (pH approx. 13)
4.0 mmol/lR2: Picric acid (pH approx. 1.2)
2.0 mg/dlStandard
Assay procedure




Measurement:  against distilled water.
 Fifty µl of standard (sample or control) was added to 1 ml of working
reagent, add and mixed well.
 The Mixture was incubated for 60 sec then absorbance (A1) was recorded.
 After exactly further 120 sec the absorbance (A2) was measured.
Calculation
∆A = (A1 – A2) sample or standard
Creatinine (mg/dl) =
A∆A sample X concentration of standard∆
standard
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Reference value (in serum) (PCLTG, 2005).
Infant 0.2 – 0.4 mg/dl
Child 0.3 - 0.7 mg/dl
Adolescent 0.5 - 1.0 mg/dl
Adult:  Male
Female
0.6 - 1.2 mg/dl
0.5 -1.1 mg/dl
3.10 Statistical analysis
Data were computer analyzed using SPSS/ PC (Statistical Package for the Social
Science Inc. Chicago, Illinois USA, version 18.0) statistical package.
Simple distribution of the study variables and the cross tabulation were applied.
Chi-square (2) was used to identify the significance of the relations,
associations, and interactions among various variables. Yates’s continuity
correction test, 2(corrected), was used when not more than 20% of the cells had an
expected frequency of less than five and when the expected numbers were small.
The independent sample t-test procedure was used to compare means of
quantitative variables by the separated cases into two qualitative groups such as
the relationship between cases and controls homocysteine levels.
The one-way ANOVA test was used for analysis of variance.
Pearson's correlation test was applied.
The results in all the above mentioned procedures were accepted as statistical
significant when the p-value was less than 5% (p<0.05).
Ranges as minimum and maximum values were used.
The percentage difference was calculated according to the formula:
Percentage difference equals the absolute value of the change in value, divided
by the average of the 2 numbers, all multiplied by 100.
Percent difference = (| (V1 - V2) | / ((V1 + V2)/2)) X 100.
 SPSS version 18.0 was used for plotting of correlation graphs plotting




4.1 Personal profile of the study population
Personal profile of the study population is summarized in Table 4.1. Age
classification showed that 19 (31.7%) controls and 18 (30.0%) cases were
≤45 years old. Age group 46-56 years comprised 18 (30.0%) controls and 16
(26.7%) cases. Controls and cases aged >56 years were 23 (38.3%) and 26
(43.3%), respectively. Chi-Square test showed that the difference between
controls and cases in term of age distribution was not significant (P=0.845).
The mean ages of controls and cases were 53.4±8.7and 53.9±10.1 years with
ranges of 38-68 and 39-70 years, respectively. The independent sample t-test
also showed no significant difference between mean ages of controls and
cases (P=0.669). Each control and case group comprised 34 (56.7%) males
and 26 (43.3%) females. Five (8.3%) and 55 (91.7%) of controls were single
and married, respectively compared to 10 (16.7%) and 50 (83.3%) of cases
(P=0.168). Analysis of the educational status of the study population showed
that 32 (53.3%) controls and 18 (30.0%) cases had a university degree, 20
(33.3%) and 14 (23.3%) finished secondary school, 6 (10.0%) and 6 (10.0%)
finished preparatory school, one (1.7%) and 16 (26.7%) passed primary
school, and one (1.7%) and 6 (10%) were illiterate. The difference between
the various educational levels of controls and cases was significant (P=0.001),
with ESRD was more prevalent among persons with lower educational levels.
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Mean±SD 53.4±8.7 53.9±10.1 t 0.529 0.669




















































*P-value of 2 (corrected) test.
P>0.05:not significant, P<0.05:significant.
4.2 Socioeconomic data of the study population
Table 4.2 provides socioeconomic data of the study population. The employed
controls and cases were 37 (61.7%) and 12 (20.0%) whereas 23 (38.3%)
controls and 48 (80.0%) cases were unemployed. The difference between the
two groups was significant (P=0.000), with increasing ESRD among
unemployed individuals. Regarding family income/month, significant
difference was also recorded between controls and cases (P=0.000) with
ESRD more frequent among family with less income. In addition, family
history of ESRD revealed that 2 (3.3%) controls and 16 (26.7%) cases
reported that they had family history of ESRD whereas 58 (96.7%) controls
and 44 (73.3%) cases did not (P=0.000), indicating that family history is
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associated with ESRD. Twenty (33.3%) controls were smokers compared to
15 (25.0%) cases (P=0.315).






























































*P-value of 2 (corrected) test.
** NIS: New Israeli Shekels.
P>0.05:not significant, P<0.05:significant.
4.3 Clinical data of the hemodialysis patients
Clinical data of the hemodialysis patients are presented in Table 4.3. The
mean duration of hemodialysis among patients was 3.2±2.9 year and the
mean frequency of hemodialysis per week was 2.6±0.6 sessions. The most
common self-reported disorders among the hemodialysis patients were
hypertension 49 (81.7%) and diabetes 32 (53.3%).
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4.4 Anthropometric measurements of the study
population
Anthropometric measurements of the study population are illustrated in Table
4.4. The mean weight of cases was 81.1±18.8 Kg compared to 81.9±11.1 Kg
of controls. The weight difference between cases and controls was not
significant (P=0.835). However, there was a significant difference in the mean
height of cases compared to controls (1.64±0.07 vs. 1.71±0.08 m, P=0.001).
Therefore, the difference in the body mass index (BMI) between cases and
controls was not significant (30.1±6.9 vs. 27.9±2.7 Kg/m2, P=0.109).































*Kg: kilogram, ** m: meter. ***BMI: Body mass index (Kg/m2): People with BMI=18.5-24.9
were considered to have normal weight, people with BMI=25.0-29.9 were classified
overweight, people with BMI≥30.0 were considered obese (WHO, 2000). All values are
expressed as mean ±SD. P>0.05: not significant, P<0.05:significant.
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4.5 Serum homocysteine levels of the study
population
Table 4.5 shows the average serum homocysteine levels of the study
population. There was a significant elevation in the mean level of
homocysteine in cases compared to controls (50.8±9.7 vs. 13.1±3.7 µmol/l, %
difference=118.0, P=0.000).


















4.6 Serum urea and creatinine concentrations of the
study population
Serum urea and creatinine concentrations of the study population are
illustrated in Table 4.6. The average concentrations of urea and creatinine
were found to be significantly higher in cases (169.6±42.4 and 9.96±2.40
mg/dl) compared to controls (27.4±7.1 and 0.77±0.14 mg/dl) with %
differences of 144.4 and 171.4, P=0.000.




























4.7 Hematological parameters of the study population
4.7.1 White blood cell count of the study population
Table 4.7 gives white blood cell count of the study population. There was a
significant increase in the mean level of WBCs count in cases compared to
controls (7.18±2.37 vs. 5.95±1.37 x103 cell/l, % difference=18.7, P=0.017).



















4.7.2 Red blood cell/mass indices of the study population
Red blood cell mass of the study population including red blood cell (RBC)
count, hemoglobin and hematocrit of the study population are illustrated in
Table 4.8. The means of RBC count, hemoglobin and hematocrit were found
to be lower in cases (3.12±0.54 x106 cell/ml, 8.9±1.5 gm/dl and 26.3±4.6 %)
compared to controls (4.03±0.37 x106 cell/ml, 12.8±1.6 gm/dl and 45.0±4.6 %)
with % differences of 25.4, 36.0 and 52.4%, respectively, P=0.000.
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4.7.3 Red blood cell indices of the study population
Table 4.9 shows RBC indices of the study population. The average level of
mean corpuscular volume (MCV) exhibited a non-significant decrease in
cases compared to controls (83.0±6.6 vs. 85.5±5.0 (fl), % difference=3.0,
p=0.105). However, mean corpuscular hemoglobin (MCH) displayed
significant decrease in cases (28.6±2.9 vs. 31.9±4.4 (pg), % difference=11.0,
p=0.001). In contrast, mean corpuscular hemoglobin concentration (MCHC)
was significantly increase in cases compared to controls (33.8±1.2 vs.
28.4±2.0 % and p=0.000).
Table 4.9. mean corpuscular volume (MCV), mean corpuscular hemoglobin


































4.7.4 Blood platelet count of the study population
Table 4.10 shows blood platelet count of the study population. There was a
significant difference in the mean blood platelet count between cases and
controls (266.3±111.9 vs. 222.0±54.1 x109 L, % difference=18.1, p=0.045).


















4.7.5 Hemostasis parameters of the study population
Hemostasis parameters of the study population including prothrombin time
(PT), activated partial thromboplastin time (APTT) and international
normalized ratio (INR) are presented in Table 4.11. The mean PT and INR
were significantly increase in cases compared to controls (16.2±2.6 sec and
1.23±0.17 vs. 13.5±0.4 sec and 0.97±0.07, % difference=18.2 and 23.6,
P=0.000). In contrast, the mean APTT was significantly decreased in cases
compared to controls (25.3±5.3 vs. 32.6±2.1 sec, % difference=25.2,
p=0.000).
Table 4.11. Hemostasis parameters prothrombin time (PT) and activated partial



































4.8.1 Homosycteine levels in relation to socio-demographic
data of the study population
Table 4.12 provides the relationship of homocysteine with socio-demographic
data of the study population. Results showed that the lower the educational
level, the higher the level of homocysteine (Figure 4.1). Using ANOVA test,
this inverse relationship was found to be significant (F=7.848, P=0.000). The
t-test showed that unemployed individuals had significant increase in
homocysteine level compared to employed ones (Figure 4.2, t=4.111,
P=0.000). Regarding family income, homocysteine level was increased with
decreased family income/month (Figure 4.3). This negative relation was
significant (F=9.862, P=0.000). In addition homocysteine level was
significantly higher in individuals with family history ESRD (Figure 4.4,
t=3.033, P=0.004).
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Table 4.12. Homosycteine levels in relation to sociodemographic data of the
study population








































Figure 4.1. Homocysteine level in various to educational levels

















































Figure 4.3. Homocysteine level in relation to Family income/month (NIS)















































4.8.2 Homosyctien level in relation to BMI of the study
population
Homocysteine level in relation to BMI of the study population is presented in
Table 4.13 and Figure 4.5. The Pearson correlation test showed that the
higher the BMI, the higher the level of homocysteine. This positive correlation
was not statistically significant (r=0.243, P= 0.062).






BMI (Kg/m2) 0.243 0.062
* People with BMI=18.5-24.9 were considered to have normal weight, people with BMI=25.0-
29.9 were classified overweight, people with BMI≥30.0 were considered obese (WHO, 2000).
P>0.05: not significant.
Figure 4.5. Correlation between homocysteine level and BMI of the study
Population
45
4.8.3 Homosycteine level in relation to urea and creatinine of
the study population
Table 4.14. shows the correlation between homocysteine levels with urea and
creatinine of the study population. The Pearson correlation test showed that
elevation in homocysteine level was accompanied with elevations in both urea
and creatinine. Such positive correlations were significant (Figure 4.6.
r=0.827, P=0.000 for urea and Figure 4.7. r=0.842, P=0.000 for creatinine).











Figure 4.6. Correlation between homocysteine level with urea of the study
population
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Figure 4.7. Correlation between homocysteine level with creatinine of the
study population.
4.8.4 Homosycteine level in relation to WBC count of the
study population
Homosycteine level in relation to WBC count of the study population is
illustrated in Table 4.15 and fugure 4.8. The Pearson correlation test showed
that the higher the homosycteine, the higher the WBC count. This positive
correlation was statistically significant (r=0.338, P= 0.008).







WBCs (x103 cell/l) 0.338 0.008
P<0.05: significant.
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Figure 4.8. Correlation between homocysteine level with WBC count of the
study population
4.8.5 Homosycteine level in relation to RBC mass of the study
population
Table 4.16 shows the correlation between homocysteine level with RBC
count, hemoglobin and hematocrite of the study population. The Pearson
correlation test showed that increase in homocysteine level was accompanied
with decrease in RBC count, hemoglobin and hematocrite. Such inverse
correlations were significant (Figure 4.9, r=-0.648, P=0.000; Figure 4.10, r=-
0.733, P=0.000 and Figure 4.11, r=-0.836, P= 0.000, respectively).
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RBCs (x106 cell/l) -0.648 0.000
Hb (gm/dl) -0.733 0.000
Hct (%) -0.836 0.000
All values are expressed as mean ±SD. P<0.05: significant.
Figure 4.9. Correlation between homocysteine level with RBC count of the
study population
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Figure 4.10. Correlation between homocysteine level with hemoglobin (HB)
content of the study population
Figure 4.11. Correlation between homocysteine level with hematocrit (HTC) of the
study population.
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4.8.6 Homosycteine level in relation to RBC indices of the
study population
Homosycteine level in relation to MCV, MCH and MCHC of the study
population is illustrated in Table 4.17, The Pearson correlation test showed
negative significant  correlations of homocysteine level with MCV and MCH
levels (Figure 4.12, r=-0.267, P=0.039; and Figure 4.13, r=-0.402 P=0.001,
respectively). On the other hand, there was a positive significant correlation
between homocysteine level and MCHC (Figure 4.14, r=0.789, P=0.000).







MCV (fl) -0.267 0.039
MCH (pg) -0.402 0.001
MCHC (mg/dl) 0.789 0.000
All values are expressed as mean ±SD. P<0.05: significant.
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Figure 4.12. Correlation between homocysteine level with MCV level of the
study population
Figure 4.13. Correlation between homocysteine level with MCH of the study
population.
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Figure 4.14. Correlation between homocysteine level with MCHC of the study
population
4.8.7 Homosycteine level in relation to blood platelet count of
the study population
Table 4.18 and Figure 4.15 points out the correlation between the
homocysteine level and platelet count of the study population. Pearson
corrlation test showed a positive significant correlation between homocysteine
level and platelet count (r=0.369, P= 0.000).







platelet count (x109 L) 0.369 0.000
All values are expressed as mean ±SD. P<0.05: significant
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Figure 4.15. Correlation between homocysteine level with platelet (PLT) count
of the study population
4.8.8 Homosycteine level in relation to hemostasis parameters
of the study population
Homosycteine level in relation to PT, APTT and INR of the study population is
illustrated in Table 4.19. Homosycteine level exhibited positive significant
correlations with PT, INR (Figure 4.16, r=0.564, P=0.000 and Figure 4.17,
r=0.657, P=0.000). On the other hand, an inverse significant correlation was
recorded between homocysteine level and APTT (Figure 4.18, r=-0.690,
P=0.000).
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PT (sec) 0.564 0.000
APTT (sec) -0.690 0.000
INR 0.657 0.000
All values are expressed as mean ±SD. P<0.05: significant.
Figure 4.16. Correlation between homocysteine level with PT of the study
population
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Figure 4.17. Correlation between homocysteine level with INR of the study
population





Although the number of hemodialysis patients in the Gaza Strip has been
doubled in the last decade with mortality rate of 2.8%, the published data on
the ESRD are few and restricted to annual reports produced by the
Palestinian Ministry of Health. The available biochemical and hematological
tests of ESRD were limited to routine traditional kidney function including urea
and creatinine tests and CBC analysis. To our knowledge only one study
assessed parathormone, calcium and phosphorus levels in hemodialysis
patients in Gaza strip (Abo Shamala, 2008). This necessitated further
assessment of other biochemical and hematological features such as
homocystine which was recently linked to ESRD (Nasri and Baradaran, 2005
and Anees et al., 2010) as well as hemostasis paramaters (Alghythan and
Alsaeed, 2012). Introduction of homocystine test in the Gaza hospital and
clinics may be useful to get a clearer picture on the patient condition, and to
help in the disease management.
5.1 Socio-demographic characters of the study
population
The present study is a case control investigation included 60 hemodialysis
patients (34 males and 26 females) with mean age 53.9±10.1 years and 60
controls (34 males and 26 females) with mean age 53.4±8.7 years. End stage
renal disease was more prevalent among low educated individuals. This
finding is in agreement with the study of Khattak et al., (2012) who concluded
that higher education level is associated with improved survival of patients on
dialysis. The result that ESRD is more frequent among unemployed may
coincide with the idea that dialysis treatment also causes a significant change
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in daily living, disruption in work schedule and shift in social role which in turn
imposes financial, housing, marital and employment problems (Chau et al.,
2003). In addition, White et al. (2008) showed that shorter duration of
education and being unemployed increased the incidence of kidney disease.
Regarding family income, ESRD was more prevalent among families with less
income/month. This result is in agreement with that obtained by NKF (2002)
and Mahmoodreza et al., (2009) who pointed out that the dialysis patients’
families had lower socioeconomic level in comparison with the healthy
population. Finally the previous socio-demographic factors may be secondary
to other disorders like hypertension and diabetes disorders reported in
hemodialysis patients. Furthermore, ESRD was more frequent in patients with
family history of the disease, i.e. ESRD is associated with family history.
Similar results were previously documented (McClellan et al., 2007; Tsai et
al., 2010 and Kong et al., 2013). In the context of socio-demographic
aspects, Sajadi et al., (2010) reported that fatigue in chronic renal failure
patients treated with hemodialysis increased with decrease in education level
and income and increase in age, dialysis history and risk of chronic renal
failure. When related to socio-demographic factors, homocysteine levels were
found to be higher among the lower educated and unemployed individuals,
among families with low income as well as among individuals with family
history of ESRD, indicating that homocysteine level could be a predictor of
ESRD in terms of education, employment, family income and family history.
Low socioeconomic status was found to be associated with an increased risk
of ESRD where homocysteine levels are elevated (Khurelbaatar and Huang
2006; Shishehbor et al., 2008 and Abo Nada, 2012).
5.2 Clinical data of the hemodialysis patients
Clinical data of the hemodialysis patients showed that the mean duration of
hemodialysis among patients was 3.2±2.9 year and the mean frequency of
hemodialysis per week was 2.6±0.6 sessions. The mean duration and
frequency of hemodialysis registered in the present study are in agreement
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with that previously obtained in hemodialysis patients in Gaza Strip by abo
Shamala (2008). The most common self-reported disorders among the
hemodialysis patients were hypertension and diabetes. This finding coincides
with the fact that high blood pressure and diabetes play a key role in the
progression of renal failure (Oishi, 2000; Whitworth, 2005; Ganesh and Lee,
2011 and Etemadi et al., 2012).
5.3 Serum homocysteine level of the study population
As indicated in the present study, there is a significant elevation in the mean
level of homocysteine in hemodialysis patients compared to controls. This
means that high homocysteine levels are linked to ESRD. Such finding is in
agreement with that demonstrated by Friedman et al. (2003); Takenaka et
al. (2005); Sjöberg et. (2006); Anees, (2010); Koning and Hu, (2010) and
Chao Wu et al. (2012). In addition, Friedman et al., (2001) reported that
hyperhomocysteinemia is very common in patients with chronic renal
insufficiency and is nearly ubiquitous in patients with end-stage renal disease;
who have up to a 30 times higher risk of cardiovascular related death than the
general population. Hyperhomocysteinemia recorded in the present study in
hemodialysis patients may be explained on the basis of: 1) homocysteine
disposal in the kidneys themselves is almost ceased and 2) extrarenal
homocysteine metabolism is impaired (van Guldener, 2006). The first
hypotheses is supported by our findings that 1) urea and creatinine was
markedly elevated in hemodialysis patients compared to controls and 2) there
was a strong positive correlation between urea and creatinine and
homocysteine (Guerra-Shinohara et al., 2007; Lu et al., 2011 and Hassan
et al., 2012).
5.4 Serum urea and creatinine concentrations of the
study population
The average concentrations of serum urea and creatinine were found to be
markedly elevated in cases compared to controls. It is known that urea and
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creatinine are markers of the kidney function (Depra Manzella, 2008).
Consequently, the present result is logic as the kidney function is almost
ceased in hemodialysis patients. Such findings are in agreement with that
previously reported in ESRD patients (Goldwasser et al., 1997; Iseki et al.,
2004; Depner, 2005; Li et al., 2009; Bmbch et al., 2010; Bhavsar et al.,
2011 and Vartia, 2013). Person’s correlation test showed significant positive
correlations of homocysteine with urea and creatinine. This implies that
hyperhomocysteinemia is linked to kidney function and that homocysteine
could be a predictive biomarker of ESRD. The recorded positive correlation of
homocysteine with urea and creatinine was previously reported (Hoffer et al.,
2000; Guerra-Shinohara et al., 2007; De Almeida et al., 2011 and Abu
Nada, 2012).
5.5 Hematological profile of the study population
White blood cell count and platelet count were significantly increased in
hemodialysis patients compared to controls. Leukocytosis recorded in the
present study is in concurrent with that obtained by Reddan et al. (2003);
Nasri, (2007); Wei Hsu et al. (2010) and Molnar et al. (2011). It is known
that hemodialysis patients suffer inflammation which is associated with
increase in WBCs (Nasri and Bradran, 2006 and Nasri, 2006; Afshar., 2009
and Molnar et al., 2011). In addition, Wei Hsu et al. (2010) pointed out that
WBC count was closely associated with index of inflammation. When related
to homosycteine level, results revealed that  the higher the homosycteine, the
higher the WBC count. This positive correlation between homosycteine level
and WBC count was reported by Ventura et al. (2004); Nasri and
Baradaran, (2005) and  Guerra-Shinohara et al. (2007).
Regarding blood plateletes, there was a significant increase in the mean
platelet count in hemodialysis patients compared to controls. Such finding is in
agreement with that demonstrated by Nasri. (2006); Molnar et al. (2011) and
Alghythan and Alsaeed. (2012). A significant positive correlation of platelet
count with serum homocysteine was found. Similar result was obtained by
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nasri (2006) who reported that in hemodialysis patients high homocystiene
levels make the platelets more likely to clump and cause clots and contributes
to the possibility of thrombotic events among these patients.
Red blood cell count, hemoglobin, hematocrit and MCH values were
significantly lower, whereas MCHC was significantly higher in hemodialysis
patients compared to controls. This indicates that hemodialysis patients are
more likely to be anemic. Such results are inagreement with that reported in
earlier studies (Besarab et al., 1998; Afshar et al., 2009; Anees et al., 2010
Mohsin et al., 2010; Suresh et al., 2012 and Poudel et al., 2013). Anemia in
hemodialysis patients may be due to many factors including blood loss,
shortened red cell life span, vitamin deficiencies, the “uremic milieu,” renal
erythropoietin deficiency due to kidney failure, iron deficiency, and
inflammation (Nurko, 2006; Locatelli et al., 2007 and Anees et al., 2010). In
addition, Shittu et al. (2013) reported that hematological parameters are
commonly affected in ESRD. Of all the parameters, red cell indices are the
ones commonly and severely affected. This is because as high as 90% of
erythropoietin is produced in the juxta glomerular apparatus of the kidney
while 10% are produced in the liver and other organs. The severity of effect
depends on the stage of renal failure. Person’s correlation test showed
negative significant correlations of homocysteine with RBC count,
hemoglobin, hematocrit and MCH values wherase MCHC exhibited a positive
significant correlation with homocysteine. Such correlations were previously
obtained by Bachmann et al. (1995); Nasri and Baradaran, (2005); Anees
et al. (2010) and Poudel et al. (2013), and reinforced the idea that
homocysteine is a suitable biomarker of ESRD, where most patients suffered
hematological disorders.
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5.6 Hemostasis parameters of the study population
The mean PT and INR were significantly increased in hemodialysis patients
compared to controls. In contrast, the mean APTT was significantly decreased
in hemodialysis patients. Such results are in agreement with that found by
Brophy et al. (2006); Ali et al. (2008) and Park et al. (2010). This means
that hemostasis process is impaired in hemodialysis patients. Jalal et al.
(2010) reported that disorders of hemostasis are associated with chronic
kidney disease. The hemostasis abnormalities in ESRD involved intrinsic and
extrinsic pathways in which there are a defect of coagulation factors and
platelets dysfunction (smits 2000; Boccardo et al., 2004; Małyszko et al.,
2005; Kaw and Malhotra, 2006; Rios et al., 2010 and Mannucci and
Tripodi, 2012). Person’s correlation test showed positive significant
correlations of homocysteine with PT and INR, whereas negative significant
correlation was recorded between homocysteine and APTT. Similar results
were reported by other authors (Shemin et al., 1999; O'shea et al., 2003;
Nasri, 2006. and Özkan and Ulusoy, 2013). Possible interactions of
homocysteine with endothelial cells, blood platelets, plasmatic fibrinogen and
plasminogen, as the important major components of hemostasis were





1. End stage renal disease was more prevalent among lower educated and
unemployed individuals, families with low income as well as among
individuals with family history of the disease.
2. Clinical data showed that hypertension and diabetes are the most common
self-reported disorders among the hemodialysis patients.
3. The mean levels of homocysteine were significantly higher in hemodialysis
patients compared to controls.
4. The average levels of urea and creatinine were significantly higher in cases
compared to controls.
5. White blood cell count, MCHC and platelete count were significantly
increased in cases compared to controls, whereas RBC count, hemoglobin,
hematocrit and MCH showed a significant decrease in cases.
6. Prothrompin time and INR were significantly increased whereas APTT was
decreased in cases compared to controls.
7. Homocysteine levels were higher among lower educated and unemployed
individuals, families with low income as well as among individuals with family
history of ESRD.
8. Homocysteine levels were positively correlated with urea, creatinine, WBC
count, MCHC and platelet count, whereas negative correlations were found
between homocysteine and RBC count, hemoglobin, hematocrit and MCH
values.
9. Homocysteine levels showed positive correlations with PT and INR and
negative correlation with APTT.
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6.2 Recommendations
1. Introducing of homocysteine as a prognostic test for ESRD patients in Gaza
hospitals and clinics is highly recommended.
2. Frequent monitoring of homocysteine levels particularly in hypertensive and
diabetic individuals as well as individuals with family history of ESRD.
3. Launching of health education programs on risk factors contributing to
ESRD particularly in hypertensive and diabetic individuals.
4. Further research on the relation of homocysteine with clotting factors and
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2. Patient No : ------------------------------------------------------------------------------
3. Age (Year):-------------------------------------------------------------------------------
4. Gender: □ Male □ Female
5. Marital status: □Single  □Married  □ Widowed  □Divorced
6. Education:□University □ Secondary school  □ Preparatory school
□Primary school  □Illiterate
7. Employment: □  Yes  □ No
8. Family history: □  Yes  □ No
9. Income/month:<1000       1000-2000         > 2000 NIS
10.Smoking :□Yes □ No
B. Medical information:
1. Date of  diagnosis:----------------------------------------------------------------------
2. When did you start hemodialysis? -------------------------------------------------
3. How many times you receive hemodialysis per week? ----------------------
4. Do you complain any other disease? □  Yes  □ No







2. Patient No : -------------------------------------------------------------------------
3. Residence: □Gaza North □ Gaza □ Mid Zone □ Gaza South
4. Age (Year): --------------------------------------------------------------------------
5. Gender: □ Male □ Female
6. Marital status: □Single □Married □Widowed
□Divorced
7. Education: □University     □ Secondary school    □ Preparatory
school□Primary school □    Illiterate
8. Employment: □  Yes  □ No
9. Family history: □  Yes  □ No
10. Income/month:<1000 1000-2000 > 2000 NISincome:
11.Smoking: □Yes □ No
